ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study

Sponsor
University of Chicago (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05084833
Collaborator
National Cancer Institute (NCI) (NIH), St. Jude Children's Research Hospital (Other), Memorial Sloan Kettering Cancer Center (Other), Columbia University (Other), Hunter College of City University of New York (Other), The Hospital for Sick Children (Other), Duke University (Other)
315
4
3
44.6
78.8
1.8

Study Details

Study Description

Brief Summary

The primary purpose of this study is to assess the best method for encouraging high-risk cancer survivors to get screened for colorectal cancer at the recommended age.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Control
  • Behavioral: Patient activation
  • Behavioral: Primary care provider activation
N/A

Detailed Description

This is a 12-month, 3-arm randomized controlled trial of 315 Childhood Cancer Survivor Study (CCSS) survivors using a text message intervention with data collected at baseline and 12 months through patient and provider surveys and interviews and a medical record review. Participants will be randomly assigned to one of three groups: control, patient activation (PA) using a text message/video intervention, or patient activation + primary care provider activation (PA + PCP) which will include providing primary care providers with resources about colorectal cancer risk in this population. All participants will receive electronic resources about their previous cancer treatment and colorectal cancer screening recommendations.

The primary outcome is the proportion of patients who complete the colonoscopy or Cologuard test (Cologuard test plus colonoscopy if the Cologuard is positive) within 12 months of enrolling on the study, as measured via self-report questions in the end of study questionnaire. The study will test the hypothesis that, compared to controls, survivors randomized to the PA and PA + PCP activation groups will have significantly higher rates of completion of colorectal cancer screening.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
315 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study
Actual Study Start Date :
Feb 14, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Nov 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group1: Control (C)

Electronic educational materials (C).

Behavioral: Control
Electronic educational materials

Experimental: Group 2: Patient Activation (PA)

C + patient activation (PA) consisting of interactive tailored text messages with links to videos and resources

Behavioral: Control
Electronic educational materials

Behavioral: Patient activation
Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants

Experimental: Group 3: Patient Activation and PCP Activation (PA + PCP)

C + PA + PCP activation (PA+PCP) with physician materials about colorectal cancer risk in this population

Behavioral: Control
Electronic educational materials

Behavioral: Patient activation
Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants

Behavioral: Primary care provider activation
Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers

Outcome Measures

Primary Outcome Measures

  1. Proportion of patients who report completing a colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization [12 months]

    This will be measured by self-report on a questionnaire given at 12 months.

Secondary Outcome Measures

  1. Proportion of patients who complete the colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization as measured in medical record reports [12 months]

    The study team will confirm if participants had a colonoscopy or cologuard test by reaching out to the medical site where the participant was screened, and requesting the medical record confirmation.

  2. Potential barriers and facilitators to the uptake of the intervention at both the patient and provider level as measured by CFIR questions [14 months]

    Consolidated Framework for Implementation Research (CFIR) questions are included in the 12-month questionnaire for participants, the 12-month questionnaire for their primary care providers, and the end of study interviews for the participants, primary care providers, and other medical office staff. CFIR questions are meant to measure 5 domains: intervention characteristics, outer setting, inner setting, characteristics of individuals, and process.

  3. Other potential barriers and facilitators to the uptake of the intervention at both the patient and provider level [12 months]

    In this study, the potential moderators include patient characteristics, such as age, gender, educational attainment, health insurance coverage, types of insurance, chronic health conditions, and race/ethnicity as well as PCP factors such as knowledge, years in practice, and practice setting. The potential mediators in this study may include the patient's perception of involvement in decision making, health insurance coverage, and whether the patient reviewed the study resources and videos. This will be measured through data collected via the baseline and 12 month questionnaires as well as data previously collected via the St. Jude Childhood Cancer Survivor Study.

  4. Cost and Cost-Effectiveness Analysis [12 months]

    We will collect data on the replication costs of the intervention and health services from the intervention per participant. The costs of the intervention (e.g. intervention materials, personnel time, and texting costs) will be collected by the University of Chicago team via a cost spreadsheet. The cost of the health services will be collected via the 12-month questionnaire; participants will be asked to share information about the types of medical visits they have had since joining the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Eligible participants will include people who:
  • Enrolled on the Childhood Cancer Survivor Study

  • Were treated with radiation to the abdomen, pelvis, spine, or total body irradiation

  • Have no history of colorectal cancer

  • Have no family history of colorectal cancer

  • Have not had a colonoscopy in the last 5 years or Cologuard in the last 3 years

  • Have a smartphone

Exclusion Criteria:
  • Do not reside in the United States

  • Do not speak English

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Chicago Chicago Illinois United States 60637
2 Memorial Sloan Kettering Cancer Center New York New York United States 10017
3 Columbia University New York New York United States 10027
4 St. Jude Children's Research Hospital Memphis Tennessee United States 38105

Sponsors and Collaborators

  • University of Chicago
  • National Cancer Institute (NCI)
  • St. Jude Children's Research Hospital
  • Memorial Sloan Kettering Cancer Center
  • Columbia University
  • Hunter College of City University of New York
  • The Hospital for Sick Children
  • Duke University

Investigators

  • Principal Investigator: Tara O Henderson, MD, MPH, University of Chicago
  • Principal Investigator: Karen Kim, MD, MS, University of Chicago

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tara Henderson, Associate Professor, University of Chicago
ClinicalTrials.gov Identifier:
NCT05084833
Other Study ID Numbers:
  • IRB20-1247
  • R01CA255269-01
First Posted:
Oct 20, 2021
Last Update Posted:
Mar 3, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Tara Henderson, Associate Professor, University of Chicago
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2022